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ABSTRACT 
 
Background: 
Non-adherence to antihypertensive medicines limits their effectiveness, increases the risk 
of adverse health outcome and is associated with significant healthcare costs. The 
multiple causes of non-adherence differ both within and between patients and are 
influenced by patients‟ care settings.  
Objectives: 
To identify determinants of patient non-adherence to antihypertensive medicines, 
drawing from psychosocial and economic models of behaviour.  
Methods: 
Hypertensive outpatients from Austria, Belgium, England, Germany, Greece, Hungary, 
Netherlands, Poland and Wales were recruited to a cross-sectional online survey.  Non-
adherence to medicines was assessed using the Morisky Medication Adherence Scale 
(primary outcome) and the Medication Adherence Rating Scale. Associations with 
adherence and non-adherence were tested for demographic, clinical, and psychosocial 
factors. 
Results: 
2595 patients completed the questionnaire. The percentage of patients classed as non-
adherent ranged from 24% in the Netherlands to 70% in Hungary. Low age, low self-
efficacy and respondents‟ perceptions of their illness and cost-related barriers were 
associated with non-adherence measured on the Morisky scale across several countries.  
In multilevel, multivariate analysis, low self-efficacy (OR 0.73, 95% CI 0.70 to 0.77) and 
a high number of perceived barriers to taking medicines (OR 1.70, 95% CI 1.38 to 2.09), 
*Blinded Manuscript [no author details]
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were the main significant determinants of non-adherence. Country differences explained 
11% of the variance in non-adherence. 
Conclusions: 
Amongst the variables measured, patients‟ adherence to antihypertensive medicines is 
influenced primarily by their self-efficacy, illness beliefs and perceived barriers. These 
should be targets for interventions for improving adherence, as should an appreciation of 
differences among the countries in which they are being delivered. 
 
INTRODUCTION 
 
 
Adherence to antihypertensive treatments is sub-optimal (1), even among patients 
participating in clinical studies, whose median persistence with medicines is only about 
one year (2). Patients who are poorly adherent (proportion of days covered ≤40%) (3) 
experience significantly increased risk of acute cardiovascular events, compared to those 
who adhere adequately (≥80%), and incur greater healthcare costs (4). The World Health 
Organisation (5) has called for further research to gain a better understanding of the 
determinants of non-adherence to antihypertensive medicines, and to identify common 
risk factors for non-adherence across different countries, in order to inform strategies for 
improving patient adherence. 
 
Known determinants of non-adherence to antihypertensive treatments may broadly be 
categorised to factors related to the patient (6-9) and their familial and cultural context 
(10), condition (11), treatment (8,11), socioeconomics, and health professional / 
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healthcare system (5,12). Components of sociocognitive and self-regulatory theory 
including attitude (13), perceived behavioural control (13-14), low self-efficacy (13,15-
16), lack of perceived treatment benefits (11), perceived barriers (7-8), illness perceptions 
(6,10), beliefs about medicines (6,11,17-18) and lack of social support (10,19-20) are 
significantly associated with non-adherence. Studies based on consumer demand theory 
support the negative impact of the costs of medicines on adherence (21), but there is a 
lack of empirical evidence on alternative behavioural economic theories such as time 
preference. We are unaware of any study in which a range of these factors has been tested 
simultaneously to assess their combined contribution to non-adherence across several 
countries. 
 
The aim of this study, therefore, was to identify determinants of patient non-adherence to 
antihypertensive medicines, drawing from psychosocial and economic models of 
behaviour, from a cross-sectional survey across a number of European countries with 
contrasting cultures, healthcare systems and patient characteristics. 
 
METHODS 
The research used an online, convenience cross-sectional sample of adults with 
hypertension recruited from 11 European countries. We tested the contribution of 
multiple, theory-driven determinants for association with antihypertensive treatment non-
adherence, and reported our findings according to the STROBE (STrengthening the 
Reporting of OBservational studies in Epidemiology) statement on cross-sectional studies 
(22). 
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Procedure 
 
Following receipt of ethical approval from all relevant committees we invited 
ambulatory, adult patients with hypertension to participate in an online questionnaire.  
Patients self-selected into this study in response to advertisements placed in community 
pharmacies (Austria, Belgium, England, France, Germany, Greece, Netherlands, 
Portugal, Poland, Wales) or hypertension clinics (Hungary). Additional strategies were 
necessary to increase recruitment in some countries. These included recruiting patients 
via general practice surgeries (Poland, Hungary), placing advertisements in the press 
(England, Wales), and using online patient support groups (Poland). No incentive was 
offered for patients to participate. The survey was administered anonymously through 
SurveyMonkey
®
, with one entry allowed per Internet Protocol address to reduce the 
chance of multiple responses. Patient information sheets, consent forms and eligibility 
checks, were provided online.  
 
Inclusion criteria 
 
We included patients who consented, and who self-reported as being: aged ≥18 years, 
diagnosed by a doctor as having hypertension that lasted at least 3 months, currently 
prescribed antihypertensive medicine(s), and personally responsible for administering 
their medicines. 
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Exclusion criteria 
 
Respondents who self-reported as being diagnosed with a “psychiatric condition” or those 
living in a nursing home (or similar facility) were excluded. 
 
Potential determinants 
 
Potential determinants of non-adherence were identified from published literature reviews 
(23-24). The questionnaire was developed from validated instruments, where available, 
and covered: participant demographics, use of medicines, self-rated health (25), and a 
battery of scales derived from economic (21) and sociocognitive (23-24) theories.  
 
Affordability and cost-related behaviours were assessed by a dichotomous question 
asking whether respondents had to think about the money available to spend when 
obtaining their medicines and six related items, each measured on a 5-point Likert scale 
(26). Components of the European Social Survey (27) assessed household income: 
participants reported their main source of income, their total annual income (in bands), 
whether they were coping with their present income and the ease or difficulty in 
borrowing money when in need.  We assessed participants‟ time preference for near, 
versus distant enjoyment of health benefits (28). The internationally standardised 
EUROPEP measure (29) assessed participants‟ evaluations of the health care they 
receive. 
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Validated, self-report tools were used to assess personal and socio-cognitive determinants 
of non-adherence. Dispositional optimism was measured using the Life Orientation Test 
(LOT-R) on 5-point Likert scales (30). Illness representations were measured using the 
Brief Illness Perception Questionnaire (B-IPQ) (31) that assessed personal beliefs about 
illness consequence, timeline, personal control, treatment control, illness identity, 
concern about illness, illness coherence and emotional representations (the causal 
subscale was removed due to translation issues). The Beliefs about Medicines 
Questionnaire (32) assessed participants‟ belief in the necessity of their medicines and 
also concerns about their medicines. Components of the Theory of Planned Behaviour 
(33-34) measured attitudes/behaviours towards taking medicines, subjective norms of 
adherence, barriers to, and facilitators of, adherence, intention to adhere and self-efficacy 
for adherence behaviours, each scored on a 5-point Likert scale. The BRIGHT 
questionnaire (35-36) was used to assess constraints/facilitators of adherence using 
subscales for barriers and social support. 
 
Outcome measures 
 
The primary outcome measure was self-reported non-adherence, based on the 4-item 
Morisky Medication Adherence Scale (37). This classified patients as being non-adherent 
according to a single „yes‟ response to any of the four questions that made specific 
reference to “high blood pressure medicine”. This validated scale is the most frequently 
used questionnaire measuring adherence to medication (38). An exploratory analysis was 
also conducted of those categorised as intentionally non-adherent based on „yes‟ 
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responses to two specific Morisky items which identify non-adherence as a result of 
feeling better/worse. A secondary outcome measure of adherence was provided by the 
Medication Adherence Rating Scale (MARS) (39), which consisted of 5 items rated on a 
Likert scale with a low score (on a range of 5 to 25) indicating lower levels of adherence. 
Our choice of outcome measures was informed by the theoretical and empirical literature 
on medication adherence spanning the behavioural and medical sciences from which the 
study questions emerged. These two conceptually different measures provided 
dichotomous data on non-adherence and continuous data on adherence to patients‟ 
antihypertensive medications.   
 
The final survey had a total of 135 items (see Supplementary Material). 
 
Translation 
 
Measures that were not validated and available in the required language were translated 
into the appropriate languages using accredited translators who were native speakers of 
the target languages and fluent in English. Translations were checked for compatibility 
with the original version in a process of back translation, performed by persons who were 
native English speakers and fluent in each target language, to ensure that none of the 
original meaning was lost. For each language, a third individual acted as a reviewer and 
highlighted any discrepancies between the forward and back translations which were 
resolved by discussion with the translators. All translations were coordinated by one 
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project partner to ensure consistency. Piloting in each country enabled identification of 
any semantic inconsistencies. 
 
Sample size 
 
Based on an expectation of 30% non-adherence (6) and a one-sided, 5% level of 
significance, 323 completed Morisky scores were required per country for within-country 
analyses.  
 
Data analysis 
 
Responses to the survey were coded in SPSS version 19 (IBM Corporation) and analysed 
in Stata version 10 (StataCorp LP). We assumed missing data to be missing at random 
and imputed using multiple imputation by chained equations (MICE) (40), to create 25 
data sets for each country. For a single incomplete variable, multiple imputation 
constructs a model relating the incomplete variable to variables in the prediction model, 
and draws from the posterior predictive distribution of the missing data, conditional on 
the observed data. Using MICE, imputed values were initialised by drawing at random 
from observed values. Imputation of missing data was performed on variables ordered by 
level of „missingness‟, using observed and current imputed values of all predictors. To 
ensure stability, this imputation step was cycled 10 times for each of the 25 imputed data 
sets (41). Analyses were performed on each set and imputation-specific coefficients were 
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pooled according to Rubin‟s rules (42). Imputed data were used for all analyses with the 
exception of demographic variables where data from complete cases were used. 
 
In the primary analysis, we calculated the percentage of patients classed as non-adherent 
according to Morisky score in each country. Potential associations with non-adherence 
were initially tested univariately using χ2 and independent samples t-tests (associations 
with medicines use were adjusted for age), followed by a logistic regression with non-
adherence as the dependent variable. We applied a bivariate method of selecting 
explanatory variables, whereby only variables found to be significant (p<0.05) in the 
univariate analysis were entered into the regression model based on a theoretical order 
(43-44), from determinants classified as demographic and medicines use characteristics 
(distal) to attitudes and behaviours (proximal). Assumptions regarding multicollinearity, 
singularity, normality, linearity, and homoscedasticity were tested and met. Country 
comparison analysis was conducted using χ2 tests. We adopted a similar approach for the 
secondary outcome of MARS adherence, but with a one-way ANOVA to test differences 
among countries.  
 
In order to account for variance both within-country and between-country, as a secondary 
analysis, 2-level multilevel regression models with respondents nested within country 
were specified for both Morisky (logit model) total and intentional non-adherence, and 
MARS adherence (linear regression model). Multilevel models with random intercepts 
and fixed effects were specified, initially with all variables common to all countries.  
Non-contributory variables were subsequently removed iteratively, determined by highest 
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p-value using backwards elimination (based on p>0.05). We calculated the variance 
partition coefficient (45), to determine the attribution of country to the observed variance 
in non-adherence. 
 
A complete case analysis of Morisky total non-adherence was performed to assess the 
sensitivity of our main findings to assumptions relating to missing data. In a post hoc 
analysis, we assessed the impact of excluding Hungary from the analysis, given that 
Hungary alone recruited patients from hypertension clinics. 
 
RESULTS 
 
Participants: A total of 2630 adults from 11 countries completed the questionnaire. Target 
recruitment was achieved in 5 countries (Austria, England, Hungary, Poland and Wales). 
Study set-up and initiation was delayed in Belgium, Germany, Greece and The 
Netherlands leading to non-target recruitment. The analysis therefore includes these 9 
countries which each recruited over 100 participants (n=2595). There was an inadequate 
level of available research support in France and Portugal that resulted in low response 
(n=11, n=33 respectively) and these were excluded from the analysis. Included 
participants‟ characteristics are presented in Table 1. The overall level of missing data by 
country ranged from 5% to 26%, with lowest rates seen on demographic and clinical 
questions (0-8%), MARS (<2%), medicine necessity and concerns (14%) and self-
efficacy (14%) and highest rates seen on the income questions (22%), Time Preference 
(22%) and Bright Barriers (23%) (Figure 1). 
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There were significant differences between country samples on all demographic and 
clinical characteristics assessed. Self-rated health was more often rated as poor or fair in 
Poland (48.6%) and Hungary (47.6%) than in Belgium (16.1%), England (19.5%) and 
Wales (19.8%). Fewer respondents from Hungary, Greece and Poland had received 
higher education than in other countries. Respondents from Greece tended to be older and 
more predominantly female, and together with Hungary and Austria, had the greatest 
number of co-morbidities and were more likely to be taking medicines more frequently 
than 3 times per day. 
 
Insert Table 1 and Figure 1 
 
Prevalence of non-adherence 
 
Based on Morisky scores, non-adherence was least prevalent in the Netherlands, and 
most prevalent in Hungary (Table 2). Intentional non-adherence was highest in Greece. 
Polish respondents had significantly lower levels of adherence, as measured by MARS, 
than respondents from other countries. 
 
Insert Table 2 
 
Associations with Morisky non-adherence and MARS adherence 
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Among demographic factors, only age showed associations across several countries with 
younger age associated with Morisky non-adherence in Austria, Belgium, Netherlands 
and Wales (Table 3), and older age associated with MARS adherence in the Netherlands 
(Table 4). Unemployment was associated with non-adherence in England and Hungary 
only. None of the medicines-related factors showed associations with non-adherence in 
more than one country. The perceived ease or difficulty in borrowing money was 
associated with non-adherence in England and Germany and having available strategies 
to cope with the costs of medicines were significantly associated with MARS-rated 
adherence in Belgium, England, Greece and Hungary. 
 
No significant associations were evident for optimism but in contrast, beliefs about the 
illness did play a significant role. B-IPQ factors of low perceived illness consequences, 
low concern about illness, and low beliefs in personal control over illness were 
significantly associated with non-adherence on the Morisky scale in Austria, Greece 
Poland and Wales (Table 3); and high belief in treatment control, high illness coherence, 
high belief in personal control significant in Austria, Greece and Hungary based on 
MARS assessment of adherence (Table 4). Illness identity, perceived illness timeline and 
emotional representations were not significant, neither were beliefs about medicines, in 
terms of their necessity or concerns about taking them (BMQ). 
 
The socio-cognitive variables, drawn mainly from the theory of planned behaviour 
(TPB), did not emerge consistently in the inter-country analysis. Perceived barriers to 
adherence (whether changes to daily routine makes taking medicines more difficult) were 
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related only to non-adherence in Greece, although a high number of barriers assessed by 
the BRIGHT (35-36) were associated with non-adherence in Austria and Poland. 
Intention to adhere was associated with adherence in Hungary and Wales. Low self-
efficacy, however, emerged significant in relation to non-adherence in all countries 
except the Netherlands, and high self-efficacy explained adherence in all countries except 
Poland. Social support factors emerged significant only in Hungary but in a counter-
intuitive direction, in relation to low perceived environmental support and greater 
adherence. 
 
The variables examined in this study explained between 13.4% and 65.2% of the 
variability in MARS adherence (Table 4).  
 
Insert Tables 3 and 4 
 
Multilevel model 
 
The multilevel logit model for Morisky non-adherence identified males, being of younger 
age, being employed, low number of medicines, high dosing frequency, high normative 
beliefs, low self-efficacy, high perceived barriers, low personal control, low concern 
about illness and difficulty in borrowing money as being significantly associated with 
non-adherence (Table 5). Associations were consistent in the model specified with 
Morisky intentional non-adherence. Multilevel linear regression found older age, a lower 
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level of education, a greater number of medicines, less frequent dosing, having low 
perceived barriers, low perceptions of illness consequences, beliefs in treatment control, 
and high self-efficacy were connected to higher adherence as measured by MARS. Based 
on the Morisky scale, 11% and 7% of explained variances in total and intentional non-
adherence were attributable to differences among countries; and 23% of the variance in 
adherence based on MARS was attributable to differences among countries. 
 
Sensitivity analysis 
 
The analysis of complete cases resulted in less precise estimators, as expected, altering 
the significance of some variables and hence their inclusion in the final model 
(Supplementary Material). However, self-efficacy and perceived barriers (BRIGHT) 
remained significant as in the primary analysis. 
 
When Hungary was excluded from the multilevel model (due to the aforementioned 
difference in recruitment method), we observed a reduction in between-country variance 
in Morisky non-adherence (from 11% to 4%). Other factors emerged as being significant, 
including education, number of medical conditions, attitudes and intention to adhere; 
though self-efficacy and barriers remained significant. 
 
DISCUSSION 
 
15 
 
Self-reported non-adherence to antihypertensive medicines is prevalent, even among the 
sampled population who were in receipt of a current prescription for antihypertensive 
treatment. Prevalence differs significantly across countries but while a proportion of this 
variance is explained by country-level effects and demographic characteristics, our 
principal finding is that potentially modifiable factors of low perceived self-efficacy and, 
to a lesser extent, low personal control beliefs, and high perceived barriers are 
consistently associated with non-adherence. Perceived barriers to adherence included 
forgetfulness or interruption of daily routine, practical difficulties, and feeling 
overwhelmed by circumstances or complexity of regimen. Our finding of common 
associations with non-adherence across different countries supports the importance of 
these factors, particularly given the significant differences that exist in cultural, medical 
practices and healthcare systems that contribute to a small proportion of the variance in 
non-adherence. 
 
Adherence is generally explained by the converse of the above but additionally, cost-
related behaviour (i.e. strategies to cope with the cost of prescriptions) and intention also 
emerged as significant in several countries. The multilevel analysis of all countries show 
that whilst many factors act in the opposite direction depending on whether we are 
addressing non-adherence or adherence, some uniquely explain non-adherence e.g. 
employment status, low normative beliefs, low personal control, low illness concern, and 
low borrowing potential; and others uniquely explain adherence e.g. lower education, low 
perceived illness consequences, (both these are counter-intuitive) and beliefs in treatment 
control. The multilevel analyses also suggest that where possible, a reduction in dose 
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frequency and number of prescribed medicines might achieve improvements in 
adherence. 
 
The literature on adherence to medicines contains many analyses that have tested the 
significance of clinical, treatment and demographic characteristics as predictors of non-
adherence, assuming that behaviour is a function of these characteristics alone. This 
approach has significant limitations.  Our analysis is rooted in behavioural theories to 
reflect the notion that individual beliefs and social influences are potentially more 
relevant determinants of intentional and non-intentional non-adherence (and of 
adherence) than relatively fixed attributes of the person or their clinical situation. 
Previous studies have shown that, based on socio-cognitive and self-regulation theories, 
personal and perceived control (6,10,13,15-16), perceived benefits of treatment (7,11) 
and perceived barriers – such as forgetfulness and experienced or anticipated side effects 
(7,8) are significant predictors of non-adherence in patients taking antihypertensive 
medicines. Associations between higher levels of self-efficacy and adherence in patients 
with hypertension have been noted previously (13,46). 
 
The novelty and key strength of our study is that a range of theoretically informed factors 
derived from behavioural theories in health psychology and economics were tested 
concurrently across several European countries. Our analysis also considered the 
distinction between intentional and unintentional non-adherence. Associations with 
intentional non-adherence were fewer, and although several overlapped with those 
associated with overall non-adherence i.e. age, self-efficacy and perceived barriers, other 
17 
 
factors included the number of medical conditions, concerns about medicines, perceived 
illness identity and behavioural intention. The act of deliberately choosing to avoid taking 
medicines, therefore, warrants interventions which more explicitly target illness and 
treatment and behavioural beliefs.  
 
There are several caveats to our analysis, however, which may limit the strength of the 
interpretations.  First, only five of the intended eleven countries reached target 
recruitment. We pragmatically included all 9 countries which recruited an appreciable 
number of patients, however this reduced the precision of the estimates of non-adherence 
in each country and limited the strength of inferences.  Second, our analyses might be 
confounded by differences in methods of recruitment. While all countries–except 
Hungary–recruited via community pharmacies, the exclusion of Hungary from the 
secondary analysis resulted in more variables being significant. However, the main 
findings of the primary (per country) analysis remained unchanged. Third, as responses 
were elicited via self-administered questionnaires, we had no means of confirming 
hypertension diagnosis, nor other responses, or mitigate any self-presentation bias which 
would reduce the external validity of our findings. Fourth, we were unable to assess the 
impact of non-response bias (47) as those who failed to complete the outcome measures–
which were at the beginning of the questionnaire–were not allowed to progress through 
the remainder of the survey.  The length of the survey (135 items) represents a fifth 
limitation, which may have impacted on completion rates.  However, the variables 
ultimately emerging as being associated with non-adherence and adherence (i.e. TPB 
barriers and self-efficacy) had relatively low levels of missingness and we improved 
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precision by performing multiple imputation. While multiple imputation addresses 
problems in complete case analyses related to loss of efficiency and bias due to 
differences between observed and unobserved data, it is no substitute for a complete 
dataset and requires an important but unverifiable assumption that data are missing at 
random. Moreover, only subscale totals rather than every individual item were imputed 
for health psychology measures. This may introduce bias as data from respondents who 
completed some, but not all, of the items in a subscale were discarded. Sixth, whilst 
employing validated scales wherever possible, full testing of the BRIGHT measure did 
not exist at the time of the study. Finally, self-reported measures of adherence are prone 
to bias (38), and may not distinguish between failure to initiate dosing, incorrect 
implementation of the dosing regimen and treatment discontinuation (48).  In mitigation, 
however, we employed two measures of adherence, and both had a significant association 
with self-efficacy.  
 
Notwithstanding these limitations, the findings can inform the development of non-
adherence reducing (or adherence-enhancing) interventions. Most importantly, the 
common variables identified within our study are amenable to change through improved 
communication with health care professionals or brief cognitive-behavioural intervention. 
Reviews of adherence-improving interventions (49-50) offer support for self-efficacy 
enhancement, with modest effects reported in trials of supportive and individually 
tailored telephone calls, information on self-management, checks on understanding and 
concerns regarding medicines and empowerment. Our analysis suggests that a 
theoretically informed, controlled trial of cognitive-behavioural interventions, focused at 
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increasing self-efficacy and related control beliefs and reducing perceived barriers to 
adherence behaviours is warranted. Given the broad spectrum of potential barriers and the 
observation of independent, country-level differences, which may be related to cultural, 
health service or other factors, interventions which are tailored specifically to the 
population in which they are being delivered are the most likely to be effective.  
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ABSTRACT 
 
Background: 
Non-adherence to antihypertensive medicines limits their effectiveness, increases the risk 
of adverse health outcome and is associated with significant healthcare costs. The 
multiple causes of non-adherence differ both within and between patients and are 
influenced by patients‟ care settings.  
Objectives: 
To identify determinants of patient non-adherence to antihypertensive medicines, 
drawing from psychosocial and economic models of behaviour.  
Methods: 
Hypertensive outpatients from Austria, Belgium, England, Germany, Greece, Hungary, 
Netherlands, Poland and Wales were recruited to a cross-sectional online survey.  Non-
adherence to medicines was assessed using the Morisky Medication Adherence Scale 
(primary outcome) and the Medication Adherence Rating Scale. Associations with 
(non)adherence and non-adherence were tested for demographic, clinical, and 
psychosocial factors. 
Results: 
2595 patients completed the questionnaire. The percentage of patients classed as non-
adherent ranged from 24% in the Netherlands to 70% in Hungary. Low age, low self-
efficacy and respondents‟ perceptions of their illness and cost-related barriers were 
associated with non-adherence measured on the Morisky scale across several countries.  
In multilevel, multivariate analysis, low self-efficacy (OR 0.73, 95% CI 0.70 to 0.77) and 
a high number of perceived barriers to taking medicines (OR 1.70, 95% CI 1.38 to 2.09), 
*Marked Manuscript [no author details]
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were the main significant determinants of non-adherence. 11% of the variance in non-
adherence was due to cCountry differences explained 11% of the variance in non-
adherence. 
Conclusions: 
Amongst the variables measured, patients‟ adherence to antihypertensive medicines is 
influenced primarily by their self-efficacy, illness beliefs and perceived barriers. These 
should be targets for interventions for improving adherence, as should an appreciation of 
differences among the countries in which they are being delivered. 
 
INTRODUCTION 
 
 
Adherence to antihypertensive treatments is sub-optimal (1), even among patients 
participating in clinical studies, whose median persistence with medicines is only about 
one year (2). Patients who are poorly adherent (proportion of days covered ≤40%) (3) 
experience significantly increased risk of acute cardiovascular events, compared to those 
who adhere adequately (≥80%), and incur greater healthcare costs (4). The World Health 
Organisation (5) has called for further research to gain a better understanding of the 
determinants of non-adherence to antihypertensive medicines, and to identify common 
risk factors for non-adherence across different countries, in order to inform strategies for 
improving patient adherence. 
 
Known determinants of non-adherence to antihypertensive treatments may broadly be 
categorised to factors related to the patient (6-9) and their familial and cultural context 
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(10), condition (11), treatment (8,11), socioeconomics, and health professional / 
healthcare system (5,12). Components of sociocognitive and self-regulatory theory 
including attitude (13), perceived behavioural control (13-14), low self-efficacy (13,15-
16), lack of perceived treatment benefits (11), perceived barriers (7-8), illness perceptions 
(6,10), beliefs about medicines (6,11,17-18) and lack of social support (10,19-20) are 
significantly associated with non-adherence. Studies based on consumer demand theory 
support the negative impact of the costs of medicines on adherence (21), but there is a 
lack of empirical evidence on alternative behavioural economic theories such as time 
preference. We are unaware of any study in which a range of these factors has been tested 
simultaneously to assess their combined contribution to non-adherence across several 
countries. 
 
The aim of this study, therefore, was to identify determinants of patient non-adherence to 
antihypertensive medicines, drawing from psychosocial and economic models of 
behaviour, from a cross-sectional survey across a number of European countries with 
contrasting cultures, healthcare systems and patient characteristics. 
 
METHODS 
The research used an online, convenience cross-sectional sample of adults with 
hypertension recruited from 11 European countries. We tested the contribution of 
multiple, theory-driven determinants for association with antihypertensive treatment non-
adherence, and reported our findings according to the STROBE (STrengthening the 
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Reporting of OBservational studies in Epidemiology) statement on cross-sectional studies 
(22). 
 
Procedure 
 
Following receipt of ethical approval from all relevant committees we invited 
ambulatory, adult patients with hypertension to participate in an online questionnaire.  
Patients self-selected into this study in response to advertisements placed in community 
pharmacies (Austria, Belgium, England, France, Germany, Greece, Netherlands, 
Portugal, Poland, Wales) or hypertension clinics (Hungary). Additional strategies were 
necessary to increase recruitment in some countries. These included recruiting patients 
via general practice surgeries (Poland, Hungary), placing advertisements in the press 
(England, Wales), and using online patient support groups (Poland). No incentive was 
offered for patients to participate. The survey was administered anonymously through 
SurveyMonkey
®
, with one entry allowed per Internet Protocol address to reduce the 
chance of multiple responses. Patient information sheets, consent forms and eligibility 
checks, were provided online.  
 
Inclusion criteria 
 
We included patients who consented, and who self-reported as being: aged ≥18 years, 
diagnosed by a doctor as having hypertension that lasted at least 3 months, currently 
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prescribed antihypertensive medicine(s), and personally responsible for administering 
their medicines. 
 
Exclusion criteria 
 
Respondents who self-reported as being diagnosed with a “psychiatric condition” or those 
living in a nursing home (or similar facility) were excluded. 
 
Potential determinants 
 
Potential determinants of non-adherence were identified from published literature reviews 
(23-24). The questionnaire was developed from validated instruments, where available, 
and covered: participant demographics, use of medicines, self-rated health (25), and a 
battery of scales derived from economic (21) and sociocognitive (23-24) theories.  
 
Affordability and cost-related behaviours were assessed by a dichotomous question 
asking whether respondents had to think about the money available to spend when 
obtaining their medicines and six related items, each measured on a 5-point Likert scale 
(26). Components of the European Social Survey (27) assessed household income: 
participants reported their main source of income, their total annual income (in bands), 
whether they were coping with their present income and the ease or difficulty in 
borrowing money when in need.  We assessed participants‟ time preference for near, 
versus distant enjoyment of health benefits (28). The internationally standardised 
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EUROPEP measure (29) assessed participants‟ evaluations of the health care they 
receive. 
 
Validated, self-report tools were used to assess personal and socio-cognitive determinants 
of non-adherence. Dispositional optimism was measured using the Life Orientation Test 
(LOT-R) on 5-point Likert scales (30). Illness representations were measured using the 
Brief Illness Perception Questionnaire (B-IPQ) (31) that assessed personal beliefs about 
illness consequence, timeline, personal control, treatment control, illness identity, 
concern about illness, illness coherence and emotional representations (the causal 
subscale was removed due to translation issues). The Beliefs about Medicines 
Questionnaire (32) assessed participants‟ belief in the necessity of their medicines and 
also concerns about their medicines. Components of the Theory of Planned Behaviour 
(33-34) measured attitudes/behaviours towards taking medicines, subjective norms of 
adherence, barriers to, and facilitators of, adherence, intention to adhere and self-efficacy 
for adherence behaviours, each scored on a 5-point Likert scale. The BRIGHT 
questionnaire (35-36) was used to assess constraints/facilitators of adherence using 
subscales for barriers and social support. 
 
Outcome measures 
 
The primary outcome measure was self-reported non-adherence, based on the 4-item 
Morisky Medication Adherence Scale (37). This classes classified patients as being non-
adherent according to a single „yes‟ response to any of the four questions that made 
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specific reference to “high blood pressure medicine”. This validated scale is the most 
frequently used questionnaire measuring adherence to medication (38). An exploratory 
analysis was also conducted of those categorised as intentionally non-adherent based on 
„yes‟ responses to two specific Morisky items which identify non-adherence as a result of 
feeling better/worse. A secondary outcome measure of adherence was provided by the 
Medication Adherence Rating Scale (MARS) (39), which consists consisted of 5 items 
rated on a Likert scale with a low score (on a range of 5 to 25) indicating lower levels of 
adherence. Our choice of outcome measures was informed by the theoretical and 
empirical literature on medication adherence spanning the behavioural and medical 
sciences from which the study questions emerged. These two measures are conceptually 
different measures, provideding dichotomous data on non-adherence and continuous data 
on adherence to patients‟ antihypertensive medications.   
 
The final survey had a total of 135 items (see Supplementary Material). 
 
Translation 
 
Measures that were not validated and available in the required language were translated 
into the appropriate languages using accredited translators who were native speakers of 
the target languages and fluent in English. Translations were checked for compatibility 
with the original version in a process of back translation, performed by persons who were 
native English speakers and fluent in each target language, to ensure that none of the 
original meaning was lost. For each language, a third individual acted as a reviewer and 
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highlighted any discrepancies between the forward and back translations which were 
resolved by discussion with the translators. All translations were coordinated by one 
project partner to ensure consistency. Piloting in each country enabled identification of 
any semantic inconsistencies. 
 
Sample size 
 
Based on an expectation of 30% non-adherence (6) and a one-sided, 5% level of 
significance, 323 completed Morisky scores were required per country for within-country 
analyses.  
 
Data analysis 
 
Responses to the survey were coded in SPSS version 19 (IBM Corporation) and analysed 
in Stata version 10 (StataCorp LP). We assumed missing data to be missing at random 
and imputed using multiple imputation by chained equations (MICE) (40), to create 25 
data sets for each country. For a single incomplete variable, multiple imputation 
constructs a model relating the incomplete variable to variables in the prediction model, 
and draws from the posterior predictive distribution of the missing data, conditional on 
the observed data. Using MICE, imputed values were initialised by drawing at random 
from observed values. Imputation of missing data was performed on variables ordered by 
level of „missingness‟, using observed and current imputed values of all predictors. To 
ensure stability, this imputation step was cycled 10 times for each of the 25 imputed data 
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sets (41). Analyses were performed on each set and imputation-specific coefficients were 
pooled according to Rubin‟s rules (42). Imputed data were used for all analyses with the 
exception of demographic variables where data from complete cases were used. 
 
In the primary analysis, we calculated the percentage of patients classed as non-adherent 
according to Morisky score in each country. Potential associations with non-adherence 
were initially tested univariately using χ2 and independent samples t-tests (associations 
with medicines use were adjusted for age), followed by a logistic regression with non-
adherence as the dependent variable. We applied a bivariate method of selecting 
explanatory variables, whereby only variables found to be significant (p<0.05) in the 
univariate analysis were entered into the regression model based on a theoretical order 
(43-44), from determinants classified as demographic and medicines use characteristics 
(distal) to attitudes and behaviours (proximal). Assumptions regarding multicollinearity, 
singularity, normality, linearity, and homoscedasticity were tested and met. Country 
comparison analysis was conducted using χ2 tests. We adopted a similar approach for the 
secondary outcome of MARS adherence, but with a one-way ANOVA to test differences 
among countries.  
 
In order to account for variance both within-country and between-country, as a secondary 
analysis, 2-level multilevel regression models with respondents nested within country 
were specified for both Morisky (logit model) total and intentional non-adherence, and 
MARS adherence (linear regression model). Multilevel models with random intercepts 
and fixed effects were specified, initially with all variables common to all countries.  
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Non-contributory variables were subsequently removed iteratively, determined by highest 
p-value using backwards elimination (based on p>0.05). We calculated the variance 
partition coefficient (45), to determine the attribution of country to the observed variance 
in non-adherence. 
 
A complete case analysis of Morisky total non-adherence was performed to assess the 
sensitivity of our main findings to assumptions relating to missing data. In a post hoc 
analysis, we assessed the impact of excluding Hungary from the analysis, given that 
Hungary alone recruited patients from hypertension clinics. 
 
RESULTS 
 
Participants: A total of 2630 adults from 11 countries completed the questionnaire. Target 
recruitment was achieved in 5 countries (Austria, England, Hungary, Poland and Wales). 
Study set-up and initiation was delayed in Belgium, Germany, Greece and The 
Netherlands leading to non-target recruitment. The analysis therefore includes these 9 
countries which each recruited over 100 participants (n=2595). There was an inadequate 
level of available research support in France and Portugal that resulted in low response 
(n=11, n=33 respectively) and these were excluded from the analysis. Included 
participants‟ characteristics are presented in Table 1. The overall level of missing data by 
country ranged from 5% to 26%, with lowest rates seen on demographic and clinical 
questions (0-8%), MARS (<2%), medicine necessity and concerns (14%) and self-
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efficacy (14%) and highest rates seen on the income questions (22%), Time Preference 
(22%) and Bright Barriers (23%) (Figure 1). 
 
There were significant differences between country samples on all demographic and 
clinical characteristics assessed. Self-rated health was more often rated as poor or fair in 
Poland (48.6%) and Hungary (47.6%) than in Belgium (16.1%), England (19.5%) and 
Wales (19.8%). Fewer respondents from Hungary, Greece and Poland had received 
higher education than in other countries. Respondents from Greece tended to be older and 
more predominantly female, and together with Hungary and Austria, had the greatest 
number of co-morbidities and were more likely to be taking medicines more frequently 
than 3 times per day. 
 
Insert Table 1 and Figure 1 
 
Prevalence of non-adherence 
 
Based on Morisky scores, non-adherence was least prevalent in the Netherlands, and 
most prevalent in Hungary (Table 2). Intentional non-adherence was highest in Greece. 
Polish respondents had significantly lower levels of adherence, as measured by MARS, 
than respondents from other countries. 
 
Insert Table 2 
 
Associations with Morisky non-adherence and MARS adherence 
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Among demographic factors, only age showed associations across several countries with 
younger age associated with Morisky non-adherence in Austria, Belgium, Netherlands 
and Wales (Table 3), and older age associated with MARS adherence in the Netherlands 
(Table 4). Unemployment was associated with non-adherence in England and Hungary 
only. None of the medicines-related factors showed associations with non-adherence in 
more than one country. The perceived ease or difficulty in borrowing money was 
associated with non-adherence in England and Germany and having available strategies 
to cope with the costs of medicines were significantly associated with MARS-rated 
adherence in Belgium, England, Greece and Hungary. 
 
No significant associations were evident for optimism but in contrast, beliefs about the 
illness did play a significant role. B-IPQ factors of low perceived illness consequences, 
low concern about illness, and low beliefs in personal control over illness were 
significantly associated with non-adherence on the Morisky scale in Austria, Greece 
Poland and Wales (Table 3); and high belief in treatment control, high illness coherence, 
high belief in personal control significant in Austria, Greece and Hungary based on 
MARS assessment of adherence (Table 4). Illness identity, perceived illness timeline and 
emotional representations were not significant, neither were beliefs about medicines, in 
terms of their necessity or concerns about taking them (BMQ). 
 
The socio-cognitive variables, drawn mainly from the theory of planned behaviour 
(TPB), did not emerge consistently in the inter-country analysis. Perceived barriers to 
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adherence (whether changes to daily routine makes taking medicines more difficult) were 
related only to non-adherence in Greece, although a high number of barriers assessed by 
the BRIGHT (35-36) were associated with non-adherence in Austria and Poland. 
Intention to adhere was associated with adherence in Hungary and Wales. Low self-
efficacy, however, emerged significant in relation to non-adherence in all countries 
except the Netherlands, and high self-efficacy explained adherence in all countries except 
Poland. Social support factors emerged significant only in Hungary but in a counter-
intuitive direction, in relation to low perceived environmental support and greater 
adherence. 
 
The variables examined in this study explained between 13.4% and 65.2% of the 
variability in MARS adherence (Table 4).  
 
Insert Tables 3 and 4 
 
Multilevel model 
 
The multilevel logit model for Morisky non-adherence identified males, being of younger 
age, being in employedment, low number of medicines, high dosing frequency, high 
normative beliefs, low self-efficacy, high perceived barriers, low personal control, low 
concern about illness and difficulty in borrowing money to as being associated 
significantly associated with non-adherence (Table 5). Associations were consistent in the 
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model specified with Morisky intentional non-adherence. Multilevel linear regression 
found older age, a lower level of education, a greater number of medicines, less frequent 
dosing, having low perceived barriers, low perceptions of illness consequences, beliefs in 
treatment control, and high self-efficacy were connected to higher adherence as measured 
by MARS. Based on the Morisky scale, 11% and 7% of explained variances in total and 
intentional non-adherence were attributable to differences among countries; and 23% of 
the variance in adherence based on MARS was attributable to differences among 
countries. 
 
Sensitivity analysis 
 
The analysis of complete cases resulted in less precise estimators, as expected, altering 
the significance of some variables and hence their inclusion in the final model 
(Supplementary Material). However, self-efficacy and perceived barriers (BRIGHT) 
remained significant as in the primary analysis. 
 
With the exclusion ofWhen Hungary was excluded from the multilevel model (due to the 
aforementioned difference in recruitment method), we observed a reduction in between-
country variance in Morisky non-adherence (from 11% to 4%). Other factors emerged as 
being significant, including education, number of medical conditions, attitudes and 
intention to adhere; though self-efficacy and barriers remained significant. 
 
DISCUSSION 
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Self-reported non-adherence to antihypertensive medicines is prevalent, even among the 
sampled population who were in receipt of a current prescription for antihypertensive 
treatment. Prevalence differs significantly across countries but while a proportion of this 
variance is explained by country-level effects and demographic characteristics, our 
principal finding is that potentially modifiable factors of low perceived self-efficacy and, 
to a lesser extent, low personal control beliefs, and high perceived barriers are 
consistently associated with non-adherence. Perceived barriers to adherence included 
forgetfulness or interruption of daily routine, practical difficulties, and feeling 
overwhelmed by circumstances or complexity of regimen. Our finding of common 
associations with non-adherence across different countries supports the importance of 
these factors, particularly given the significant differences that exist in cultural, medical 
practices and healthcare systems that contribute to a small proportion of the variance in 
non-adherence. 
 
Adherence is generally explained by the converse of the above but additionally, with 
cost-related behaviour (i.e. strategies to cope with the cost of prescriptions) and intention 
also emerged as significanting in several countries. The multilevel analysis of all 
countries show that whilst many factors act in the opposite direction depending on 
whether we are addressing non-adherence or adherence, some uniquely explain non-
adherence e.g. employment status, low normative beliefs, low personal control, low 
illness concern, and low borrowing potential; and others uniquely explain adherence e.g. 
lower education, low perceived illness consequences, (both these are counter-intuitive) 
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and beliefs in treatment control. The multilevel analyses also suggest that where possible, 
a reduction in dose frequency and number of prescribed medicines might achieve 
improvements in adherence. 
 
The literature on adherence to medicines contains many analyses that have tested the 
significance of clinical, treatment and demographic characteristics as predictors of non-
adherence, assuming that behaviour is a function of these characteristics alone. This 
approach has significant limitations.  Our analysis is rooted in behavioural theories to 
reflect the notion that individual beliefs and social influences are potentially more 
relevant determinants of intentional and non-intentional non-adherence (and of 
adherence) than relatively fixed attributes of the person or their clinical situation. 
Previous studies have shown that, based on socio-cognitive and self-regulation theories, 
personal and perceived control (6,10,13,15-16), perceived benefits of treatment (7,11) 
and perceived barriers – such as forgetfulness and experienced or anticipated side effects 
(7,8) are significant predictors of non-adherence in patients taking antihypertensive 
medicines. Associations between higher levels of self-efficacy and adherence in patients 
with hypertension have been noted previously (13,46). 
 
The novelty and key strength of our study is that a range of theoretically informed factors 
derived from behavioural theories in health psychology and economics were tested 
concurrently across several European countries. Our analysis also considered the 
distinction between intentional and unintentional non-adherence. Associations with 
intentional non-adherence were fewer, and although several overlapped with those 
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associated with overall non-adherence i.e. age, self-efficacy and perceived barriers, other 
factors included the number of medical conditions, concerns about medicines, perceived 
illness identity and behavioural intention. The act of deliberately choosing to avoid taking 
medicines, therefore, warrants interventions which more explicitly target illness and 
treatment and behavioural beliefs.  
 
There are several caveats to our analysis, however, which may limit the strength of the 
interpretations.  First, only five of the intended eleven countries reached target 
recruitment. We pragmatically included all 9 countries which recruited an appreciable 
number of patients, however this reduced the precision of the estimates of non-adherence 
in each country and limited the strength of inferences.  Second, our analyses might be 
confounded by differences in methods of recruitment. While all countries–except 
Hungary–recruited via community pharmacies, the exclusion of Hungary from the 
secondary analysis resulted in more variables being significant. However, the main 
findings of the primary (per country) analysis remained unchanged. Third, as responses 
were elicited via self-administered questionnaires, we had no means of confirming 
hypertension diagnosis, nor other responses, or mitigate any self-presentation bias which 
would reduce the external validity of our findings. Fourth, we were unable to assess the 
impact of non-response bias (47) as those who failed to complete the outcome measures–
which were at the beginning of the questionnaire–were not allowed to progress through 
the remainder of the survey.  The length of the survey (135 items) represents a fifth 
limitation, which may have impacted on completion rates.  However, the variables 
ultimately emerging as being associated with non-adherence and adherence (i.e. TPB 
18 
 
barriers and self-efficacy) had relatively low levels of missingness and we improved 
precision by performing multiple imputation. While multiple imputation addresses 
problems in complete case analyses related to loss of efficiency and bias due to 
differences between observed and unobserved data, it is no substitute for a complete 
dataset and requires an important but unverifiable assumption that data are missing at 
random. Moreover, only subscale totals rather than every individual item were imputed 
for health psychology measures. This may introduce bias as data from respondents who 
completed some, but not all, of the items in a subscale were discarded. Sixth, whilst 
employing validated scales wherever possible, full testing of the BRIGHT measure did 
not exist at the time of the study. Finally, self-reported measures of adherence are prone 
to bias (38), and may not distinguish between failure to initiate dosing, incorrect 
implementation of the dosing regimen and treatment discontinuation (48).  In mitigation, 
however, we employed two measures of adherence, and both had a significant association 
with self-efficacy.  
 
Notwithstanding these limitations, the findings can inform suggest a number of 
implications for the development of non-adherence reducing (or adherence-enhancing) 
interventions. Most importantly, the common variables identified within our study are 
amenable to change through improved communication with health care professionals or 
brief cognitive-behavioural intervention. Reviews of adherence-improving interventions 
(49-50) offer support for self-efficacy enhancement, with modest effects reported in trials 
of supportive and individually tailored telephone calls, information on self-management, 
checks on understanding and concerns regarding medicines and empowerment. Our 
19 
 
analysis suggests that a theoretically informed, controlled trial of cognitive-behavioural 
interventions, focused at increasing self-efficacy and related control beliefs and reducing 
perceived barriers to adherence behaviours is warranted. Given the broad spectrum of 
potential barriers and the observation of independent, country-level differences, which 
may be related to cultural, health service or other factors, interventions which are tailored 
specifically to the population in which they are being delivered are the most likely to be 
effective.  
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Table 1. Demographic data and cross country comparison 
 
Explanatory 
variable 
Country (number respondents) 
χ2 
p-value 
Austria 
(323) 
Belgium 
(180) 
England 
(323) 
Germany 
(274) 
Greece 
(289) 
Hungary 
(323) 
Netherlands 
(237) 
Poland 
(323) 
Wales 
(323) 
Age - mean 
(95% CI) 
60.2 
(58.8, 61.5) 
57.3 
(55.6, 59.1) 
59.6 
(58.5, 60.7) 
56.8 
(55.4, 58.2) 
63.9 
(62.6, 65.2) 
58.2 
(56.8, 59.7) 
58.3 
(57.0, 59.5) 
54.5 
(53.2, 55.8) 
61.1 
(59.9, 62.2) 
16.62 
p < 0.001 
df = 8 
Sex (female, 
%) 
145 
(44.9%) 
64 
(35.6%) 
141 
(43.7%) 
154 
(56.2%) 
173 
(59.9%) 
179 
(55.4%) 
115 
(48.5%) 
171 
(52.9%) 
119 
(36.8%) 
64.54 
p < 0.001  
df = 8 
Education 
Secondary 
only* 
120 
(37.2%) 
6 
(3.3%) 
110 
(34.1%) 
51 
(18.6%) 
148 
(51.2%) 
253 
(78.3%) 
7 
(3.0%) 
167 
(51.7%) 
98 
(30.3%) 
64.54 
p < 0.001 
df = 8 Higher 
education 
194 
(60.1%) 
174 
(96.7%) 
211 
(65.3%) 
222 
(81.0%) 
135 
(46.7%) 
68 
(21.1%) 
229 
(96.6%) 
155 
(48.0%) 
224 
(69.3%) 
Marital status 
Married 
209 
(64.7%) 
134 
(74.4%) 
241 
(74.6%) 
184 
(67.2%) 
187 
(64.7%) 
234 
(72.4%) 
186 
(78.5%) 
246 
(76.2%) 
258 
(79.9%) 
36.11 
p < 0.001 
df = 8 
Student / in 
employment 
119 
(36.8%) 
98 
(54.4%) 
166 
(51.4%) 
150 
(54.7%) 
119 
(41.2%) 
124 
(38.4%) 
151 
(63.7%) 
169 
(52.3%) 
143 
(44.3%) 
70.47 
p < 0.001 
df = 8 
Health status 
Poor 
23 
(7.1%) 
4 
(2.2%) 
10 
(3.1%) 
6 
(2.2%) 
0 
(0%) 
26 
(8.0%) 
5 
(2.1%) 
24 
(7.4%) 
13 
(4.0%) 
322.59 
p < 0.001 
df = 24 
Fair 
96 
(29.7%) 
25 
(13.9%) 
53 
(16.4%) 
84 
(30.7%) 
93 
(32.2%) 
128 
(39.6%) 
49 
(20.7%) 
133 
(41.2%) 
51 
(15.8%) 
Good 
128 
(39.6%) 
77 
(42.8%) 
123 
(38.1%) 
140 
(51.1%) 
140 
(48.4%) 
132 
(40.9%) 
112 
(47.3%) 
138 
(42.7%) 
116 
(35.9%) 
Very good 
74 
(22.9%) 
72 
(40.0%) 
137 
(42.4%) 
44 
(16.1%) 
55 
(19.0%) 
36 
(11.1%) 
69 
(29.1%) 
28 
(8.6%) 
142 
(44.0%) 
Mean number 
of medical 
conditions 
(95% CI) 
2.84 
(2.59, 3.08) 
2.29 
(2.10, 2.47) 
2.28 
(2.15, 2.42) 
2.13 
(1.97, 2.30) 
2.85 
(2.64, 3.06) 
2.85 
(2.68, 3.02) 
2.08 
(1.93, 2.24) 
2.15 
(2.02, 2.27) 
2.42 
(2.26, 2.57) 
13.16 
p < 0.001 
df = 8 
Mean number 
of medicines 
(95% CI) 
4.43 
(4.06, 4.79) 
3.54 
(3.19, 3.90) 
3.84 
(3.58, 4.10) 
3.42 
(3.14, 3.70) 
4.37 
(3.99, 4.75) 
5.17 
(4.80, 5.53) 
3.44 
(3.09, 3.79) 
4.12 
(3.83, 4.42) 
3.80 
(3.54, 4.06) 
12.01 
p < 0.001 
df = 8 
Mean units of 5.51 3.78 4.93 3.92 5.06 7.44 4.31 3.20 4.97 22.41 
Table1
medicines per 
day (95% CI) 
(4.95, 6.07) (3.33, 4.23) (4.45, 5.40) (3.56, 4.27) (4.57, 5.54) (6.90, 7.98) (3.45, 5.16) (2.89, 3.51) (4.45, 5.49) p < 0.001 
df = 8 
Most 
frequently 
dosed 
medicine 
Once daily 
114 
(35.3%) 
123 
(68.3%) 
224 
(9.3%) 
100 
(36.5%) 
51 
(17.6%) 
54 
(16.7%) 
157 
(66.2%) 
131 
(40.6%) 
241 
(74.6%) 
557.56 
p < 0.001 
df = 16 
Twice daily 
110 
(34.1%) 
35 
(19.4%) 
63 
(19.5%) 
129 
(47.1%) 
112 
(38.8%) 
155 
(48.0%) 
56 
(23.6%) 
143 
(44.3%) 
47 
(14.6%) 
≥ Thrice daily 
96 
(29.7%) 
19 
(10.6%) 
26 
(8.0%) 
44 
(16.1%) 
123 
(42.6%) 
113 
(35.0%) 
22 
(9.3%) 
48 
(14.9%) 
35 
(10.8%) 
 
Data are counts (%), unless otherwise indicated.  
* Secondary education meaning to secondary (high) school level 
 
 
Table 2. Prevalence of self-reported total non-adherence and intentional non-adherence across European countries based on Morisky responses, 
and adherence based on MARS 
 
 Morisky MARS 
 Respondents self-reporting as being 
non-adherent (as a percentage of all 
respondents) (95% Confidence 
Interval) 
Respondents self-reporting as being 
intentionally non-adherent (as a 
percentage of non-adherers) (95% 
Confidence Interval) 
Mean score (95% Confidence 
Interval)* 
The Netherlands 24.1 (18.6, 29.5) 21.1 (10.5, 31.6) 23.86 (23.64, 24.16) 
Germany 33.2 (27.6, 38.8) 35.2 (25.4, 45.0) 23.47 (23.28, 23.75) 
Austria 33.7 (28.6, 38.9) 51.4 (42.0, 60.8) 23.25 (23.03, 23.56) 
Wales 38.1 (32.8, 43.4) 25.2 (17.5, 32.9) 23.46 (23.30, 23.77) 
Belgium 38.9 (31.8, 46.0) 17.1 (8.3, 26.0) 23.59 (23.50, 23.99) 
England 41.5 (36.1, 46.9) 23.9 (16.7, 31.1) 23.41 (23.17, 23.65) 
Greece 50.2 (44.4, 55.9) 57.2 (49.2, 65.3) 22.08 (21.71, 22.48) 
Poland 57.6 (52.2, 63.0) 44.6 (37.5, 51.8) 18.19 (17.77, 19.01) 
Hungary 70.3 (65.3, 75.3) 18.1 (13.1, 23.1) 22.88 (22.74, 23.26) 
Cross country 
comparison 
χ2: 191.52 
df: 8 
p = 0.000 
Tests cross country difference in 
self-reported non-adherence 
χ 2: 108.87 
df: 8 
p = 0.000 
Tests cross country difference in 
self-reported intentional non-
adherence, as a proportion of all 
self-reported non-adherence 
ANOVA F-test: 106.08 – 115.49** 
(Complete case F: 103.24) 
p = 0.000 
*95% CI of mean based on imputed data 
**Range of imputation specific statistics 
Table 2
Table 3: Summary of the logistic regression model using the Morisky non-adherence as the dependent variable. Figures are reported as odds 
ratio (95% confidence interval) and exact p-values. 
 
 
Explanatory variable
†
 
Country 
Austria Belgium England Germany Greece Hungary Netherlands Poland Wales 
Demographics 
 Age 
0.96 
(0.93, 0.99) 
p = 0.012 
0.97 
(0.95, 1.00) 
p = 0.047 
0.98 
(0.94, 1.03) 
p = 0.431 
0.97 
(0.94, 1.01) 
p = 0.012 
  
0.94 
(0.91, 0.98) 
p = 0.001 
0.98 
(0.94, 1.00) 
p = 0.088 
0.97 
(0.93, 1.00) 
p = 0.037 
 Employment 
1.32 
(0.56, 3.13) 
p = 0.521 
 
3.14 (1.34, 
7.34) 
p = 0.008 
1.25 
(0.49, 3.19) 
p = 0.646 
 
2.93 (1.58, 
5.42) 
p = 0.001 
 
1.12 
(0.55, 2.27) 
p = 0.762 
0.82 
(0.37, 1.82) 
p = 0.618 
Socio-demographics / Clinical factors 
 Number of tablets 
0.97 
(0.88, 1.07) 
p = 0.502 
   
0.88 
(0.78, 0.98) 
p = 0.025 
    
 
Dosing frequency 
Once daily 
   
0.08 (0.03, 
0.26) 
p < 0.001 
     
 
Twice daily 
   
0.24 
(0.09, 0.62) 
p = 0.004 
     
 Income source 
0.72 
(0.31, 1.67) 
p = 0.445 
 
0.99 
(0.36, 2.73) 
p = 0.977 
3.83 
 (1.31, 11.18) 
p = 0.014 
    
1.08 
(0.45, 2.58) 
p = 0.864 
 
Borrowing income: 
Difficult 
  
6.26 
(1.14, 34.46) 
p = 0.035 
 
3.01 
(0.81, 11.12) 
p = 0.098 
1.30 
(0.64, 2.62) 
p = 0.469 
   
 
Neither difficult or 
easy 
  
5.28 
(0.93, 30.17) 
p = 0.061 
 
1.82 
(0.43, 7.72) 
p = 0.418 
3.36 
(1.34, 8.43) 
p = 0.010 
   
 Easy   
5.47 
(1.00, 29.77) 
p = 0.050 
 
3.08 
(0.65, 14.59) 
p = 0.157 
0.59 
(0.24, 1.47) 
p = 0.261 
   
 
Number of items 
prescribed 
1.06 
(0.95, 1.19) 
 
0.86 
(0.76, 0.97) 
0.84 
(0.70, 1.00) 
     
Table3
p = 0.313 p = 0.017 p = 0.051 
Illness perceptions 
 Illness consequences 
0.89 
(0.81, 0.99) 
p = 0.029 
        
 Personal control 
0.94 
(0.84, 1.04) 
p = 0.230 
 
0.94 
(0.83, 1.07) 
p = 0.333 
 
0.79 
(0.66, 0.95) 
p = 0.013 
0.93 
(0.82, 1.06) 
p = 0.289 
  
0.88 
(0.79, 0.99) 
0.031 
 
Concern about 
illness 
       
0.79 
(0.68, 0.92) 
p = 0.002 
 
Theory of planned behaviour 
 Barrier     
1.28 
(1.03, 1.60) 
p = 0.028 
 
1.26 
(0.97, 1.63) 
p = 0.078 
 
0.93 
(0.72, 1.22) 
p = 0.610 
 Self efficacy 
0.79 (0.70, 
0.90) 
p < 0.001 
 
0.82 
(0.69, 0.96) 
p = 0.016 
0.62 (0.52, 
0.74) 
p < 0.001 
0.53 (0.43, 
0.67) 
p < 0.001 
0.82 
(0.71, 0.95) 
p = 0.006 
0.84 
(0.73, 0.96) 
p = 0.013 
0.81 
(0.68, 1.04) 
p = 0.111 
0.70 
(0.60, 0.82) 
p < 0.001 
0.66 
(0.56, 0.79) 
p < 0.001 
BRIGHT 
 Barriers 
1.04 
(1.00, 1.08) 
p = 0.035 
 
1.04 
(0.98, 1.10) 
p = 0.155 
 
1.05 
(1.00, 1.10) 
p = 0.061 
1.05 
(1.00, 1.10) 
p = 0.051 
 
1.06 
(1.00, 1.11) 
p = 0.034 
1.05 
(0.99, 1.11) 
p = 0.107 
 
Constant
‡ 
 
133.99 
(6.92, 
2593.41) 
p = 0.001 
33.32 (4.06, 
273.37) 
p = 0.001 
11.78 
(0.17, 833.40) 
p = 0.256 
649.33 (28.07, 
15018.96) 
p < 0.001 
8.10 
(0.36, 183.93) 
p = 0.189  
4.13 
(0.49, 
35.10) 
p = 0.194 
33.71 
(1.92, 
591.49) 
p = 0.016 
320.84 
(9.36, 
10993.92) 
p = 0.001 
124.91 
(1.44, 
10848.02) 
p = 0.034 
Other predictors in 
model where p>0.05
§
 
2, 18, 19, 22, 
24 
20 
6, 7, 8, 9, 15, 
16, 17, 19, 20, 
25 
 
1, 9, 10, 13, 
15, 17, 19, 20, 
25 
9, 10, 17, 
23, 26 
11, 12 
10, 13, 14, 15, 
16, 22, 25 
3, 4, 5, 15, 17, 
20, 21, 23, 25 
 
Final Model χ 2 and 
p value
+
 
64.94, 78.87 
p < 0.001 
14.36,  
27.28 
p < 0.001 
104.25,  145.31 
p < 0.001 
89.41, 123.04 
p < 0.001 
76.51, 89.42 
p < 0.001 
64.02, 
81.23 
p < 0.001 
25.74, 47.98 
p < 0.001 
76.56, 120.57 
p < 0.001 
75.19, 94.15 
p < 0.001 
 
†
Only Odds ratios for predictors with p<0.05 for at least one country are presented.  
‡
Constant reported for all values of p 
§Number of medical conditions (1), Number of different medicines (2), Income deciles 1-4 (3), Income deciles 5-7 (4), Income deciles 8-10 (5), Perception of income: Living 
comfortably (6), Perception of income: Coping (7), Perception of income: Finding it difficult (8), Affordability problem (9), Cost coping strategies (10), Time preference: 
long (11), Time preference: short (12), Prescriber of medicines (13), Gender of prescriber (14), Satisfaction with practitioner (15), Satisfaction with practice (16), Optimism 
(17), Timeline (18), Treatment control (19), Illness coherence (20), Emotional representations (21),  Necessity of medicines (22),  Concern about medicine (23),  Attitude 
(24),  Intention (25),  Social Support (26) 
+As χ2 cannot be pooled, we report the range of imputation specific χ2. The degrees of freedom per imputation is given by (number of variables -1).  Imputation-specific, p-
values were p < 0.001 in all cases, with the exception of 3 imputations in Belgium (which were p=0.001, 0.001, 0.002). 
 
Table 4: Summary of the final regression model (all variables) using the MARS adherence dependent variable (-coefficient, 95% confidence 
intervals) 
 
Explanatory 
variable
†
 
Country 
Austria Belgium England Germany Greece Hungary Netherlands Poland Wales 
Demographics 
 Age 
0.01 
(-0.02, 
0.03) 
p = 0.606 
0.00 
(-0.02, 
0.03) 
p = 0.922 
0.02 
(-0.01, 0.05) 
p = 0.109 
0.02 
(-0.01, 0.04) 
p = 0.153 
  
0.03 
(0.00, 0.06) 
p = 0.026 
 
0.00 
(-0.02, 0.03) 
p = 0.976 
 Sex    
0.39 
(-0.10, 0.88) 
p = 0.119 
    
0.49 
(0.00, 0.98) 
p = 0.050 
Socio-demographic / Clinical factors 
 
Cost coping 
strategies 
-0.10 
(-0.22, 
0.01) 
p = 0.076 
-0.17 
(-0.30, -
0.06) 
p = 0.004 
-0.12 
(-0.21, -0.02) 
p = 0.020 
-0.06 
(-0.16, 0.05) 
p = 0.319 
-0.35 
(-0.42, -
0.28) 
p < 0.001 
-0.21 
(-0.28, -
0.15) 
p < 0.001 
 
-0.12 
(-0.25, 0.02) 
p = 0.094 
 
Time preference 
 Short     
7.12 
(2.14, 
12.09) 
p = 0.005 
    
Illness perceptions 
 Personal control   
0.01 
(-0.10, 0.11) 
p = 0.931 
 
-0.11 
(-0.26, 0.04) 
p = 0.144 
0.17 
(0.04, 
0.30) 
p = 0.011 
0.11 
(-0.02, 0.24) 
p = 0.102 
0.05 
(-0.24, 0.33) 
p = 0.735 
0.05 
(-0.05, 0.15) 
p = 0.348 
 
Treatment 
control 
0.26 
(0.13, 0.39) 
p < 0.001 
 
0.13 
(-0.02, 0.28) 
p = 0.095 
-0.02 
(-0.17, 0.13) 
p = 0.794 
0.08 
(-0.08, 0.24) 
p = 0.299 
-0.09 
(-0.25, 
0.07) 
p = 0.284 
 
0.11 
(-0.27, 0.50) 
p = 0.558 
0.07 
(-0.08, 0.20) 
p = 0.366 
 
Illness 
coherence 
  
-0.07 
(-0.20, 0.06) 
p = 0.274 
 
0.17 
(0.02, 0.32) 
p = 0.032 
0.08 
(-0.06, 
0.21) 
p = 0.257 
  
-0.01 
(-0.13, 0.10) 
p = 0.814 
Table4
Theory of planned behaviour 
 Intention 
-0.09 
(-0.25, 
0.07) 
p = 0.286 
 
 
0.06 
(-0.17, 0.28) 
p = 0.623 
 
0.15 
(-0.03, 0.33) 
p = 0.112 
0.32 
(0.09, 
0.55) 
p  = 0.007 
 
-0.01 
(-0.53, 0.51) 
p = 0.971 
0.33 
(0.04, 0.62) 
p = 0.028 
 Self efficacy 
0.28 
(0.16, 0.40) 
p < 0.001 
0.19 
(0.02, 
0.36) 
p = 0.027 
0.30 
(0.17, 0.42) 
p < 0.001 
0.32 
(0.19, 0.46) 
p < 0.001 
0.39 
(0.26, 0.52) 
p < 0.001 
0.15 
0.03, 0.26 
p = 0.016 
0.25 
(0.09, 0.41) 
p = 0.002 
0.29 
(-0.03, 0.61) 
p = 0.072 
0.37 
(0.22, 0.51) 
p < 0.001 
BRIGHT 
 Barriers 
-0.04 
(-0.07, 
0.00) 
p = 0.062 
-0.01 
(-0.05, 
0.03) 
p = 0.698 
-0.04 
(-0.09, 0.01) 
p = 0.081 
-0.00 
(-0.03, 0.03) 
p = 0.893 
-0.05 
(-0.09,0.01) 
p = 0.010 
-0.07 
(-0.11, -
0.03) 
p = 0.101 
 
-0.08 
(-0.17, 0.00) 
p = 0.057 
-0.06 
(-0.11, 0.00) 
p = 0.060 
 Social Support 
-0.02 
(-0.09, 
0.04) 
p = 0.520 
 
0.00 
(-0.04, 0.05) 
p = 0.920 
  
-0.05 
(-0.10, -
0.01) 
p = 0.024 
  
0.03 
(-0.02, 0.07) 
p = 0.270 
 Constant 
18.97 
(15.83, 
22.10) 
p < 0.001 
21.72 
(19.04, 
24.40) 
p < 0.001 
17.83 
(13.96, 
21.69) 
p < 0.001 
20.15 
(17.35, 
22.96) 
p < 0.001 
19.06 
(16.32, 
21.80) 
p < 0.001 
19.76 
16.70, 
22.82) 
p < 0.001 
19.48 
(17.29, 
21.68) 
p < 0.001 
13.74 
(8.97, 18.51) 
p < 0.001 
19.37 
(15.86, 
22.88) 
p < 0.001 
Other predictors in 
model where 
p>0.05
‡
 
2, 6, 11, 13, 
14, 20, 22, 
23 
11, 14, 20 
3, 8, 9, 10, 
11, 13, 14, 
15, 16, 17, 
18, 19, 20, 
22, 24 
13, 14, 16, 
17, 19, 20, 
22 
3, 5, 7, 8, 
10, 11, 12, 
14, 15, 17, 
19, 24 
1, 7, 10, 
13, 14, 15, 
16, 17, 19, 
20, 22, 23, 
24 
24 13, 21, 23 
3, 4, 5, 8, 11, 
13, 14, 15, 
16, 17, 19, 
20, 23, 24 
 Adjusted R
2
 0.2831 0.2005 0.3809 0.2223 0.6521 0.4589 0.1335 0.1482 0.3570 
 
†
Only coefficients for predictors with p<0.05 for at least one country are presented.  
 
‡
Marital status (1), Employment (2), Dosage frequency (3), Number of medicines (4), Number of medical conditions (5), Income source (6), Total income (7), Income 
perception (8), Borrowing (9), Affordability problem (10), Health status (11), Time preference: long (12), Satisfaction with practitioner (13), Satisfaction with practice (14), 
Optimism (15), Illness consequences (16), Identity (17), Concern about illness (18), Emotional representations (19), Concern about medicine (20), Necessity of medicine 
(21), Attitude (22), Normative beliefs (23), Barriers-TPB (24) 
Table 5: Summary of multilevel regression models for Morisky and MARS as outcome 
measures.  
 
 
 Morisky MARS 
Explanatory variable Odds Ratio 
95% 
Confidence 
Interval β-coefficient 
95% 
Confidence 
Interval 
Sex 1.22* 1.01, 1.47   
Age 0.98*** 0.97, 0.99 0.01* 0.00, 0.02 
Employment 0.74* 0.59, 0.94   
Education   -0.34** -0.60, -0.09 
Number of medicines 0.89*** 0.86, 0.93 0.06* 0.01, 0.10 
Dosing frequency 1.30** 1.12, 1.52 -0.24** -0.42, -0.06 
Normative beliefs 1.05* 1.01, 1.09   
Self-efficacy 0.73*** 0.70, 0.77 0.36*** 0.30, 0.42 
Barriers (BRIGHT) 1.70*** 1.38, 2.09 -0.83*** -1.10, -0.57 
Illness consequences   -0.06* -0.10, -0.01 
Personal control 0.94** 0.90, 0.97   
Treatment control   0.11** 0.04, 0.19 
Concern about illness 0.94** 0.91, 0.98   
Borrowing money 0.85** 0.78, 0.94   
Constant 34.59*** 13.5, 88.5 19.45*** 18.1, 20.8 
Random effects parameters Variance 
95% 
Confidence 
Interval 
Variance 
95% 
Confidence 
Interval 
Between country variance (σu
2
) 0.40 0.15, 1.07 2.14 0.79, 5.80 
Within country variance (σe
2
)   7.09 6.63, 7.57 
% variance attributable to 
differences between countries 
10.82 4.35, 24.49 23.20 10.63, 43.40 
 
*p<0.05, **p<0.01, ***p<0.001 
For the logit model σe
2
 =  π2/3  
Variance partition coefficient, VPC = σu
2/( σu
2+ σe
2
) 
 
Full model specification: age, sex, education, marital status, employment, number of medical 
conditions, number of different medicines, number of tablets, dosing frequency, number of 
items prescribed, health status, affordability problem, optimism, necessities, concerns about 
medicine, attitudes, normative beliefs, barrier (theory of planned behaviour), facilitators, 
intention, self-efficacy, prescriber of medicines, gender of prescriber, satisfaction with 
practitioner, satisfaction with practice, barriers (averaged as one less collected in Wales), 
social support, illness consequences, illness timeline, personal control, treatment control, 
illness symptomaticity, concern about illness, illness coherence, emotional representations, 
income source, income perception, ease of borrowing, total income. 
 
Table 5
Supplementary Material 
 
Summary of the logistic regression model using the Morisky non-adherence as the dependent variable, based on complete case data. 
Figures are reported as odds ratio (95% confidence interval) and exact p-values. 
 
Explanatory variable
*
 
Country 
Austria Belgium England Germany Greece Hungary Netherlands Poland Wales 
Demographics 
 Age 
0.95 
(0.91, 1.00) 
p = 0.048 
0.98 
(0.95, 
1.01) 
p = 0.141 
1.02 
(0.94, 1.11) 
p = 0.609 
0.96 
(0.92, 
1.01) 
p = 0.098 
  
0.91 
(0.86, .96) 
p = 0.000 
0.98 
(0.93, 1.03) 
p = 0.435 
0.98 
(0.93, 
1.03) 
p = 0.367 
 Employment 
1.47 
(0.37, 5.88) 
p = 0.589 
 
3.49 
(0.74, 16.45) 
p = 0.115 
2.64 
(0.75, 
9.33) 
p = 0.132 
 
3.81 
(1.64, 8.87) 
p = 0.002 
 
0.89 
(0.22, 3.62) 
p = 0.870 
1.05 
(0.33, 
3.39) 
p = 0.936 
Socio-demographics / Clinical factors 
 
Dosing frequency 
Once daily 
   
0.03 
(0.01, 
0.15) 
p = 0.000 
     
 
Twice daily 
   
0.12 
(0.04, 
0.39) 
p = 0.000 
     
 
Total income: 
Deciles 1 - 4 
        
1.77 
(0.37, 
8.58) 
p = 0.476 
 Deciles 5 – 7         
1.30 
(0.26, 
6.50) 
p = 0.753 
 Deciles 8 - 10         
6.94 
(1.45, 
Supplemental Material
33.22) 
p = 0.015 
 
Borrowing income: 
Difficult 
  
1.62E+09 
(0, ∞) 
p = 0.999 
 
2.66 
(0.21, 34.26) 
p = 0.454 
1.52 
(0.61, 3.77) 
p = 0.363 
   
 
Neither difficult or 
easy 
  
9.56E+08 
(0, ∞) 
p = 0.999 
 
3.27 
(0.22, 48.02) 
p = 0.388 
3.68 
(1.15, 
11.72) 
p = 0.027 
   
 Easy   
1.22E+09 
(0, ∞) 
p = 0.999 
 
4.83 
(0.23, 
100.19) 
p = 0.309 
1.04 
(0.33, 3.30) 
p = 0.942 
   
Illness perceptions 
 Personal control 
0.98 
(0.83, 1.17) 
p = 0.826 
 
0.92 
(0.76, 1.12) 
p = 0.784 
 
0.63 
(0.44, 0.91) 
p = 0.014 
0.96 
(0.82, 1.13) 
p = 0.610 
  
0.93 
(0.78, 
1.10) 
p = 0.386 
 Illness coherence  
0.85 
(0.73, 
1.00) 
p = 0.051 
0.92 
(0.72, 1.17) 
p = 0.479 
 
1.28 
(0.91, 1.79) 
p = 0.158 
   
1.30 
(1.03, 
1.64) 
p = 0.029 
Theory of planned behaviour 
 Barrier     
1.12 
(0.70, 1.81) 
p = 0.637 
 
1.49 
(1.06, 2.10) 
p = 0.023 
 
0.75 
(0.50, 
1.12) 
p = 0.156 
 Intention   
1.05 
(0.61, 1.83) 
p = 0.857 
 
0.93 
(0.56, 1.56) 
p = 0.788 
  
0.99 
(0.55, 1.76) 
p = 0.967 
0.61 
(0.38, 
0.98) 
p = 0.041 
 Self-efficacy 
0.74 
(0.61, 0.90) 
p = 0.003 
0.79 
(0.67, 
0.94) 
p = 0.008 
0.48 
(0.35, 0.67) 
p = 0.000 
0.50 
(0.39, 
0.65) 
p = 0.000 
0.70 
(0.53, 0.92) 
p = 0.010 
0.84 
(0.69, 1.01) 
p = 0.062 
0.86 
(0.65, 1.14) 
p = 0.290 
0.59 
(0.42, 0.83) 
p = 0.002 
0.54 
(0.40, 
0.73) 
p = 0.000 
BRIGHT 
 Barriers 
1.90 
(1.00, 1.18) 
p = 0.042 
 
1.16 
(1.02, 1.33) 
p = 0.027 
 
1.01 
(0.92, 1.11) 
p = 0.868 
1.09 
(1.02, 1.15) 
p = 0.009 
 
1.05 
(0.99, 1.11) 
p = 0.099 
1.13 
(1.02, 
1.26) 
p = 0.022 
 
Constant
** 
 
425.00 
p = 0.009 
41.16 
p = 0.001 
3.12 
p = 0.780 
2252.17 
p = 0.000 
2196.04 
p = 0.036 
3.87 
p = 0.352 
165.92 
p = 0.014 
359.06 
p = 0.079 
14015.57 
p = 0.008 
Other predictors in 
model where p>0.05
***
 
2, 3, 4, 5, 18, 
19, 20, 23, 25 
 
4, 5, 6, 7, 8, 9, 
15, 16, 17, 20 
4, 5 
1, 3, 9, 10, 
13, 15, 17, 
20 
9, 10, 17, 
24, 26 
11, 12 
10, 13, 14, 
15, 16, 21, 
23,  
5, 15, 17, 
22, 24 
 Final Model χ2 
41.67 
p = 0.000 
df = 14 
19.69 
p = 0.000 
df = 3 
83.25 
p = 0.000 
df = 3 
85.70 
p = 0.000 
df = 7 
41.583 
p = 0.001 
df = 17 
50.85 
p = 0.000 
df = 12 
35.44 
p = 0.000 
df = 5 
44.87 
p = 0.000 
df = 12 
77.01 
p = 0.000 
df = 16 
*
Only Odds ratios for predictors with p<0.05 for at least one country are presented.  
**
Constant reported for all values of p 
***Number of medical conditions (1), Number of different medicines (2), Number of tablets (3), Number of items on prescription (4), Income source (5), 
Perception of income: Living comfortably (6), Perception of income: Coping (7), Perception of income: Finding it difficult (8), Affordability problem (9), Cost 
coping strategies (10), Time preference: long (11), Time preference: short (12), Prescriber of medicines (13), Gender of prescriber (14), Satisfaction with 
practitioner (15), Satisfaction with practice (16), Optimism (17), Illness consequences (18), Illness timeline (19), Treatment control (20), Illness concern (21) 
Emotional representations (22), Necessity of medicines (23),  Concerns about medicine (24), Attitude (25), Social support (26). 
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Screen 2:  Eligibility filter (first screen of Survey Monkey) 
Introductory Questions 
 
Please begin by completing the questions below. 
 
After answering the questions, go to the next screen by clicking the NEXT button at the bottom. 
 
1.  Are you over 18 years old? 
 Yes 
 No 
 
2. Have you been diagnosed by your doctor as having high blood pressure (hypertension) that 
has lasted at least 3 months? 
 Yes 
 No 
 
3. Are you currently prescribed medication for high blood pressure (hypertension)? 
 Yes 
 No 
 
*4. Have you ever been diagnosed with: 
 Diabetes 
 Psoriasis 
 Psychiatric condition 
 Liver dysfunction 
 
5. Are you independent in medicines taking? 
 Yes, I am independent and self-responsible for taking my medicines 
 No, another person takes care of administration of my medicines 
 
6. Are you living in a nursing home or similar facility? 
 Yes 
 No 
 
>>NEXT>> 
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Screen 3:  Demographics 
Questions About You 
 
First, we would like to ask you questions about yourself. 
 
After answering the questions, go to the next screen by clicking the NEXT button at the bottom. 
 
1. Please select the country of your residence 
<<drop-down list of all countries involved in the survey>> 
 
2. Are you …? 
 Female 
 Male 
 
3. How old were you on your last birthday? 
 
 
4.  What is the first part of your postcode? 
   
 
5. What is the highest level of education you have achieved? 
 Primary 
 Secondary 
 Higher education 
 
6. Marital status: 
 Single 
 Married / In a civil partnership 
 Separated 
 Divorced 
 Widowed 
 
7. Employment status: 
 Working full time 
 Working part time 
 Unemployed 
 Retired 
 Student 
 On sick leave (lasting longer than 7 days) 
 Others (including unpaid work 
>>NEXT>> 
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Screen 4:  Medicines Use 
Your Use of Medicines Today 
 
1. How many medical conditions are you currently receiving prescribed medication for? 
 
 
2. Thinking of today, how many different medicines have you been prescribed to take each 
day? (please enter the number) 
 
 
3. Thinking of today, how many units of medicines (eg. tablets) have you been prescribed to 
take each day? (please enter number) 
 
 
4. How many times a day you are supposed to take your medicines? 
 
 
 
 
 
 
 
>>NEXT>>  
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Screen 5:  Health status  
Your Health  
 
1.  In general, would you say your health is...? (tick one) 
 
 Excellent 
 Very good 
 Good 
 Fair 
 Poor 
 
>>NEXT>> 
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Screen 6: Affordability 
Your Prescriptions 
 
The next questions ask you about both the number of prescriptions and items which a doctor or other 
health professional may have prescribed for you.  
 
A prescription is the sheet of paper you were issued with. A prescription may include more than one 
item (individual medicine). For example, if you received a prescription listing two medicines, the total 
number of items is two. 
 
1. As far as you can remember, during the last four weeks, how many items (individual 
medicines) have you been prescribed? 

 
2. Not relevant in Wales: go to question 3. 
  Not relevant in Wales 
  Not relevant in Wales 
  Not relevant in Wales 
 
3. Do you ever feel that you have to think about how much money you have available to spend 
when you obtain medicines? 
  Yes 
  No 
 
4. Please indicate which of the statements below applies to you: 
 
a) If I am worried about money I take less of a medicine to make it last longer  
 
Always  Often  Sometimes   Rarely  Never 
 
b) I have to leave getting my prescription dispensed until I get paid  
 
Always  Often  Sometimes   Rarely  Never 
 
c) If I have a number of different items on my prescription, I don’t get them all dispensed, because I 
can't afford them all at once 
 
Always  Often  Sometimes   Rarely  Never 
 
d) I have in the past borrowed money to pay for prescription medicines  
 
Always  Often  Sometimes   Rarely  Never 
 
e) Knowing that I will not be able to afford the prescription stops me from going to see my doctor 
 
Always  Often  Sometimes   Rarely  Never 
 
f) I ask my general practitioner / family doctor to supply a longer supply of my medicine to help me 
when I haven't got enough money 
 
Always  Often  Sometimes   Rarely  Never 
 
>>NEXT>> 
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Screen 7:  Medicines Adherence (primary outcome measure) – 4-item Morisky Questionnaire 
You indicated that you are taking medicines for high blood pressure.  People have identified several 
issues regarding their medicines-taking behavior and we are interested in your experiences. There is 
no right or wrong answer. Please answer each question based on your personal experience with your 
long-term illness medicine. 
 
1. Do you ever forget to take your high blood pressure medicine? 
  Yes  
  No 
 
2. Are you careless at times about taking your high blood pressure medicine? 
  Yes  
  No 
 
3. Sometimes if you feel worse when you take your high blood pressure medicine do you stop 
taking it? 
  Yes 
  No 
 
4. When you feel better, do you sometimes stop taking your high blood pressure medicine? 
  Yes 
  No 
>>NEXT>> 
Appendix – survey 
Morrison VL., et al. Predictors of self-reported adherence to antihypertensive medicines: A 
multi-national, cross-sectional survey. Value in Health 
 
 
Screen 8:  Medicines Adherence (secondary outcome measures) – MARS_5  
Questions About Taking Your Medicines 
 
 Many people find a way of using their medicines that suits them.   
 
 This may differ from the instructions on the label or from what their doctor has said. 
 
 We would like to ask you a few questions about how you use your medicines. 
 
Here are some ways in which people have said that they use their medicines. 
For each of the statements, please tick the dot which best applies to you. 
 
Your own way of using your medicines: 
 
1. I forget to take them 
Always  Often  Sometimes   Rarely  Never 
 
2. I alter the dose  
Always  Often  Sometimes   Rarely  Never 
 
3. I stop taking them for a while 
Always  Often  Sometimes   Rarely  Never 
 
4. I decide to miss out a dose  
Always  Often  Sometimes   Rarely  Never 
 
5. I take less than instructed 
Always  Often  Sometimes   Rarely  Never 
 
>>NEXT>> 
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Screens 9-17:  Discrete choice experiment 
(Reported elsewhere) 
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Screens 18a-d:  Time Preference Questionnaire 
Time Preference 
 
We would like you to imagine that you have been diagnosed with epilepsy. You have seizures (fits) 
that occur 20 times per year, and which seriously affect your usual activities.   
 
 
 
Imagine you start a medicine ONE YEAR from now  
that will reduce your seizures from 20 to: 
12 times per year 
 
If you do not start the medicine for FOUR YEARS from now 
What is the maximum number of seizures per year that would still make this medicine worthwhile? 
 
 
<drop-down menu 13:0> 
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Screens 18b:  Time Preference Questionnaire (cont) 
 
 
Imagine you start a medicine ONE YEAR from now  
that will reduce your seizures from 20 to: 
12 times per year 
 
If you do not start the medicine for SEVEN YEARS from now 
What is the maximum number of seizures per year that would still make this medicine worthwhile? 
 
 
<drop-down menu 13:0> 
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Screens 18c:  Time Preference Questionnaire (cont) 
 
 
Imagine you start a medicine ONE YEAR from now 
that will reduce your seizures from 20 to: 
8 times per year 
 
If you do not start the medicine for FOUR YEARS from now 
What is the maximum number of seizures per year that would still make this medicine worthwhile? 
 
 
<drop-down menu 9:0> 
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Screens 18d:  Time Preference Questionnaire (cont) 
 
 
Imagine you start a medicine ONE YEAR from now 
that will reduce your seizures from 20 to: 
8 times per year 
 
If you do not start the medicine for SEVEN YEARS from now 
What is the maximum number of seizures per year that would still make this medicine worthwhile? 
 
 
<drop-down menu 9:0> 
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Screen 19: LOT-R 8. LOT 
These questions are about you. Try not to let your response to one statement influence your 
responses to other statements. 
 
There are no "correct" or "incorrect" answers. Answer according to your own feelings, rather 
than how you think other people might answer. 
 
1. In uncertain times, I usually expect the best. 
 I agree a lot;  I agree a little;  I neither agree nor disagree;  I disagree a little;  I disagree a lot 
 
2. It's easy for me to relax.  
 I agree a lot;  I agree a little;  I neither agree nor disagree;  I disagree a little;  I disagree a lot 
 
3. If something can go wrong for me, it will. 
 I agree a lot;  I agree a little;  I neither agree nor disagree;  I disagree a little;  I disagree a lot 
 
4. I'm always optimistic about my future. 
 I agree a lot;  I agree a little;  I neither agree nor disagree;  I disagree a little;  I disagree a lot 
 
5. I enjoy my friends a lot.  
 I agree a lot;  I agree a little;  I neither agree nor disagree;  I disagree a little;  I disagree a lot 
 
6. It's important for me to keep busy. 
 I agree a lot;  I agree a little;  I neither agree nor disagree;  I disagree a little;  I disagree a lot 
 
7. I hardly ever expect things to go my way. 
 I agree a lot;  I agree a little;  I neither agree nor disagree;  I disagree a little;  I disagree a lot 
 
8. I don't get upset too easily. 
 I agree a lot;  I agree a little;  I neither agree nor disagree;  I disagree a little;  I disagree a lot 
 
9. I rarely count on good things happening to me. 
 I agree a lot;  I agree a little;  I neither agree nor disagree;  I disagree a little;  I disagree a lot 
 
10. Overall, I expect more good things to happen to me than bad. 
 I agree a lot;  I agree a little;  I neither agree nor disagree;  I disagree a little;  I disagree a lot 
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Screen 20  BMQ_S11  
Your Views About Medicines Prescribed For You19. BMQ 
 
We would like to ask you about your personal views about medicines prescribed for you. 
 
These are statements other people have made about their medicines. 
 
Please show how much you agree or disagree with them by clicking on the appropriate dot. 
 
There are no right or wrong answers. We are interested in your personal views. 
 
Views about MEDICINES PRESCRIBED FOR YOU: 
 
Strongly Agree Agree Uncertain Disagree Strongly Disagree 
 
1.  My health, at present, depends on these medicines  
Strongly Agree Agree Uncertain Disagree Strongly Disagree 
 
2.  Having to take these medicines worries me  
Strongly Agree Agree Uncertain Disagree Strongly Disagree 
 
3.  My life would be impossible without these medicines  
Strongly Agree Agree Uncertain Disagree Strongly Disagree 
 
4.  I sometimes worry about long-term effects of these medicines  
Strongly Agree Agree Uncertain Disagree Strongly Disagree 
 
5.  Without these medicines I would be very ill  
Strongly Agree Agree Uncertain Disagree Strongly Disagree 
 
6.  These medicines are a mystery to me  
Strongly Agree Agree Uncertain Disagree Strongly Disagree 
 
7.  My health in the future will depend on these medicines  
Strongly Agree Agree Uncertain Disagree Strongly Disagree 
 
8.  These medicines disrupt my life  
Strongly Agree Agree Uncertain Disagree Strongly Disagree 
 
9.  I sometimes worry about becoming too dependent on these medicines 
Strongly Agree Agree Uncertain Disagree Strongly Disagree 
 
10.  These medicines protect me from becoming worse  
Strongly Agree Agree Uncertain Disagree Strongly Disagree 
 
11.  These medicines give me unpleasant side effects  
Strongly Agree Agree Uncertain Disagree Strongly Disagree 
 
© Robert Horne 
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Screen 21: Theory of planned behavior questionnaire   
Your Beliefs About Taking Your Medicines 
 
We would like to know your beliefs about taking your medicines. 
 
Please show how much you agree or disagree with each statement by clicking on the appropriate dot. 
 
I agree a lot; I agree a little;  I neither agree or disagree;  I disagree a little;  I disagree a lot 
 
1.  If I were to take my medicines regularly................................. 
..............................they would help me to stay well 
..............................they would reduce my chances of developing complications from my illness 
..............................they would keep the cause of my illness under control  
..............................they would keep my symptoms under control  
..............................they would help me avoid needing further treatment  
..............................they would cause me unpleasant side effects (e.g. feeling sick or bloated) 
..............................they would lead to me gaining weight 
 
2.  My doctor or nurse would approve of me taking my medicines regularly  
 
3.  My wife/husband/partner would approve of me taking my medicines regularly  
 
4.  Members of my family or close relatives would approve of me taking my medicines regularly 
 
5.  Changes to my daily routine would make it more difficult for me to take my medicines regularly 
 
6.  Having a regular review with the healthcare professional would make it easier for me to take my 
medicines regularly 
 
7.  Keeping to a regular routine and being disciplined would make it easier for me to take my 
medicines regularly 
 
8.  It is likely that I will take my medicines regularly  
 
9.  I intend to take my medicines regularly  
 
10.  Putting out my tablets in a box would make it easier for me to take my medicines regularly 
 
For each of the following questions, please indicate, by placing a tick in the appropriate dot for 
each question, your level of confidence for each of the following: 
 
 Not at all confident;  Somewhat confident;  Very confident;  Extremely confident;  
Completely confident 
 
11.  Overall, how confident are you that you will always take your medications as prescribed? 
 
12.  Overall, how confident are you that you will always take your medications at the prescribed 
times? 
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Screen 22: EUROPEP21. EUROPEP 
General Health Service Use 
 
1. Which of the following is mostly involved in the care of your high blood pressure 
(hypertension)? 
 Nurse practitioner 
 General practitioner/family physician 
 Specialist/consultant - hospital based 
 Specialist/consultant - private 
 Hospital physician 
 Private practitioner 
 Occupational health physician 
 Pharmacist 
 Other 
 Not applicable 
 
2. What is the gender of the above-mentioned practitioner? 
 
 Female 
 Male 
3. What is your assessment of the healthcare practitioner (referred to above) over the last 12 
months with respect to: 
1 - Poor 2 3 4 5 - Excellent 
1. Making you feel you have time during consultation  
2. Showing interest in your personal situation  
3. Making it easy for you to tell him or her about your problem  
4. Involving you in decisions about your medical care 
5. Listening to you  
6. Keeping your records and data confidential 
7. Providing quick relief of your symptoms  
8. Helping you to feel well so that you can perform your normal daily activities 
9. Thoroughness of the approach to your problems 
10. Physical examination of you 
11. Offering you services for preventing diseases (e.g. screening, health checks, immunisations) 
12. Explaining the purpose of examinations, tests and treatments 
13. Telling you enough about your symptoms and/or illness 
14. Helping you deal with emotions related to your health status 
15. Helping understand why it is important to follow the GP's advice 
16. Knowing what has been done or told during previous contacts in the practice 
17. Preparing you for what to expect from specialists, hospital care or other care providers 
 
4. What is your assessment of the general practice over the last 12 months with respect to: 
18. The helpfulness of the practice staff (other than the doctor) to you 
19. Getting an appointment to suit you?  
20. Getting through to the practice on the telephone?  
21. Being able to talk to the general practitioner on the telephone  
22. Waiting time in the waiting room?  
23. Providing quick services for urgent health problems?  
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Screen 23:  BRIGHT – Barriers and social support22. BRIGHT (barriers & social support) 
People give different reasons why it is difficult to take their medicines or to take their 
medicines on time.  Is there anything that you recognize from the problems listed below? 
 
Please provide a response for each statement by clicking on the appropriate dot. 
 
In the past year… 
 
Never;  Occasionally;  Sometimes;  Frequently;  All the time;  Not applicable 
 
1. I ran out of medicines  
2. I was confused about which medicines to take  
3. I did not want other people to know that I have a health problem 
4. Something disrupted my daily medicine routine (e.g., I was on holiday) 
5. I was forgetful  
6. I could not afford to buy my medicines 
7. I felt depressed or overwhelmed 
8. I forgot to take my medicines with me when leaving the house 
9. I had too many medicines to take 
10. I suffered from the side effects of my medicine. 
11. I had to take too many different doses during the day 
12. I had problems swallowing the large pills of my medicines 
13. I did not like the taste of my medicines  
14. I had problems removing the medicines from the package 
15. I had problems drinking enough water to swallow the medicines  
 
People from your personal environment can support you to take your medications. The 
following questions relate to this topic. Please mark the answer which best represents how 
often you received support from people in your personal environment in the following 
situations over the past 4 weeks. 
 
In the past 4 weeks... 
 
 Never;  Occasionally;  Sometimes;  Frequently;  All the time 
16. Was there someone who reminded you to take your medicines? 
17. Was there someone who helped you to prepare the medicines? 
18. Was there someone who encouraged you to take your medicines correctly? 
19. Was there someone who gave practical tips to make it easier for you to take your medicines? 
20. Was there someone who adapted his or her own life habits (waking up, schedule…) to make it 
easier for you to take your medicines? 
21. Was there someone who understood the problems or discomfort that resulted from your 
medicines? 
22. Was there someone who reprimanded you because you didn’t take your medicines correctly? 
 
>>NEXT>> 
 
Appendix – survey 
Morrison VL., et al. Predictors of self-reported adherence to antihypertensive medicines: A 
multi-national, cross-sectional survey. Value in Health 
 
 
Screen 24: The Brief Illness Perception Questionnaire 
For the following questions, please tick the number that best corresponds to your views 
23. Brief-IPQ 
1. How much does your illness affect your life? 
0 - no affect at all 1 2 3 4 5 6 7 8 9 10 – severely affects my life 
 
2. How long do you think your illness will continue? 
0 - a very short time 1 2 3 4 5 6 7 8 9 10 - forever 
 
3. How much control do you feel you have over your illness? 
0 – absolutely no control 1 2 3 4 5 6 7 8 9 10 – extreme amount of control 
 
4. How much do you think your treatment can help your illness? 
0 - not at all 1 2 3 4 5 6 7 8 9 10 – extremely helpful 
 
5. How much do you experience symptoms from your illness? 
0 – no symptoms at all 1 2 3 4 5 6 7 8 9 10 – many severe symptoms 
 
6. How concerned are you about your illness? 
0 - not at all concerned 1 2 3 4 5 6 7 8 9 10 – extremely concerned 
 
7. How well do you feel you understand your illness? 
0 - don't understand at all 1 2 3 4 5 6 7 8 9 10 – understand very clearly 
 
8. How much does your illness affect you emotionally? (e.g. does it make you angry, scared, 
upset or 
depressed?) 
0 - not at all affected emotionally 1 2 3 4 5 6 7 8 9 10 – extremely affected emotionally 
 
9. Please list in rank-order the three most important factors that you believe caused your 
illness. The most important causes for me: 
1. 
2. 
3. 
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Screen 25:  Antibiotics 
(Reported elsewhere) 
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Screen 26: Income 
The following questions ask you about your income. This information is useful to make sure we have 
the views of people with different financial circumstances and will help us to compare the results 
between difference populations. 
 
1. Please consider the income of all household members and any income which may be 
received by the household as a whole. What is the main source of income in your household? 
 Wages or salaries 
 Income from self-employment (excluding farming) 
 Income from farming 
 Pensions 
 Unemployment/redundancy benefit 
 Any other social benefits or grants 
Income from investment, savings, insurance or property 
 Income from other sources 
 Don’t know 
 Not willing to provide 
 
2. What is your household’s total income, after tax and compulsory deductions, from all 
sources?  Please mark the letter corresponding to your answer. If you don't know the exact figure, 
please give an estimate. 
 

 Not willing to provide 
 
3. Which of the following descriptions comes closest to how you feel about your household’s 
income at present? 
 Living comfortably on present income 
 Coping on present income 
 Finding it difficult on present income 
 Finding it very difficult on present income 
 Not willing to provide 
 
4. If for some reason you were in serious financial difficulties and had to borrow money to 
make ends meet, how difficult or easy would that be? 
 Very difficult 
 Quite difficult 
 Neither easy nor difficult 
 Quite easy 
Very easy 
Not willing to provide 
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Screen 27:  The final screen – Thank you and contact information  
